Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Public ClinicalTrials.gov record NCT02760498. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goals of this study are to evaluate the clinical benefit and safety of cemiplimab in participants with metastatic (nodal or distant) Cutaneous Squamous Cell Carcinoma (CSCC), or unresectable locally advanced CSCC.
Study identification
- NCT ID
- NCT02760498
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 432 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 7, 2016 (Actual)
- Primary completion
- Oct 18, 2023 (Actual)
- Completion
- Oct 18, 2023 (Actual)
- Last update posted
- May 28, 2025
2016 – 2023
United States locations
- U.S. sites
- 26
- U.S. states
- 16
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center | Phoenix | Arizona | 85004 | — |
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| City of Hope Hospital | Duarte | California | 91010 | — |
| University of California, Los Angeles | Los Angeles | California | 90095 | — |
| Stanford University | Redwood City | California | 94063 | — |
| University of California, San Diego | San Diego | California | 92161 | — |
| University of Colorado, Denver | Aurora | Colorado | 80045 | — |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | — |
| H. Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02130 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| St. Louis University | St Louis | Missouri | 63104 | — |
| Washington University in St. Louis | St Louis | Missouri | 63110 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| New York University | New York | New York | 10016 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| University of Rochester Medical Center | Rochester | New York | 14623 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| St. Luke's Hematology Oncology Specialists | Easton | Pennsylvania | 18015 | — |
| Penn State Hershey Medical Center | Hershey | Pennsylvania | 17033 | — |
| Dermatology and Laser Center of Charleston | Charleston | South Carolina | 29407 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02760498, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 28, 2025 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02760498 live on ClinicalTrials.gov.